Everything below concerns reconstitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
"Dude, people just don't want to eat pink slime". MarketWatch. Retrieved April 4, 2012. Greene, Joel L. (April 6, 2012). "Lean Finely Textured Beef: The 'Pink Slime' Controversy". Congressional Research Service. Retrieved March 2016. Gruley, Bryan; Campbell, Elizabeth (April 12, 2012). "'Pink Slime' Furor Means Disaster For U.S. Meat Innovator". Bloomberg. Retrieved July 19, 2012. Glen, Barb (June 22, 2012). "Lessons learned for Cargill in pink slime's 'ick' factor". The Western Producer. Retrieved July 18, 2012. "Pink slime saga boosts beef exports". The Australian. June 19, 2012. Retrieved July 18, 2012. Wessler, Brett (June 25, 2012). "Former BPI employee plans lawsuit for pink slime frenzy". Drovers/CattleNetwork Magazine. Archived from the original on May 1, 2013. Retrieved July 18, 2012. Siefer, Ted (July 10, 2012). "School board votes to donate 'pink slime'". New Hampshire Union Leader. Archived from the original on June 17, 2013. Retrieved July 18, 2012. Stebbins, Christine (July 12, 2012). "Cargill buys AFA Foods Fort Worth beef processing plant". Reuters. Retrieved October 10, 2013. Engber, Daniel (October 25, 2012). "The Sliming". Slate. Retrieved March 25, 2016. Russell, Joyce (June 19, 2014). "'Pink Slime' Is Making A Comeback. Do You Have A Beef With That?". NPR. Retrieved March 24, 2016. Isidore, Chris (August 13, 2014). "'Pink slime' is back and headed for your burger". CNN Money. Archived from the original on August 16, 2014. Retrieved March 25, 2016. Sanburn, Josh (August 26, 2014). "'Pink Slime' Ground Meat is Back". Time. Retrieved March 24, 2016.
Conventional radiotherapy, limited to the involved area of tumour, is the mainstay of treatment for DIPG. The standard treatment is a total radiation dosage ranging from 5400 to 6000 cGy, administered in daily fractions of 180 to 200 cGy (5 days/week over 6 weeks). Hyperfractionated (twice-daily) radiotherapy was used previously to deliver higher radiation dosages, but did not lead to improved survival in clinical trials. Hyperfractionated radiotherapy is no longer commonly used due to lack of clinical support showing improved survival rates, the discomfort of two radiotherapy sessions a day, and an increased risk in damaging healthy organs due to higher dosages. Radiosurgery (e.g., gamma knife or cyberknife) has a role in the treatment of DIPG and may be considered in selected cases.
The next day, he warned Kluge that failure to break off the attack would "bleed white" his formations and make them incapable of defence. Kluge was sympathetic since the south flank of the 4th Army had already had to retreat under Red Army pressure and was on the defensive. Hoepner was ordered to pause his attack, with the goal of resuming it on 6 December. On 5 December 1941, with orders to attack the next day, Hoepner called a conference of chiefs-of-staff of his corps. The reports were grim: only four divisions were deemed capable of attack, three of these with limited objectives. The attack was called off; the Red Army launched its winter counter-offensive on the same day.
In 1963, paracetamol was added to the British Pharmacopoeia, and has gained popularity since then as an analgesic agent with few side-effects and little interaction with other pharmaceutical agents. Concerns about paracetamol's safety delayed its widespread acceptance until the 1970s, but in the 1980s, paracetamol sales exceeded those of aspirin in many countries, including the United Kingdom. This was accompanied by the commercial demise of phenacetin, blamed as the cause of analgesic nephropathy and hematological toxicity. Available in the U.S. without a prescription since 1955 (1960, according to another source), paracetamol has become a common household drug. In 1988, Sterling Winthrop was acquired by Eastman Kodak which sold the over the counter drug rights to SmithKline Beecham in 1994. In June 2009, an FDA advisory committee recommended that new restrictions be placed on paracetamol use in the United States to help protect people from the potential toxic effects. The maximum single adult dosage would be decreased from 1000 mg to 650 mg, while combinations of paracetamol and other products would be prohibited. Committee members were particularly concerned by the fact that the then-present maximum dosages of paracetamol had been shown to produce alterations in liver function.
Sources: en.wikipedia.org
==== Custom manufacturing ==== The products and services offered by the fine chemical industry fall into two broad categories: (1) "Exclusives" or custom manufacturing (CM) and (2) "standard" or "catalogue" products. "Exclusives", provided mostly under contract research or custom manufacturing arrangements, prevail in business with life science companies; "standards" prevail in other target markets. Service-intense custom manufacturing constitutes the most prominent activity of the fine chemical industry. Custom manufacturing is the antonym of outsourcing. In custom manufacturing, a specialty-chemicals company outsources the process development, pilot plant, and industrial-scale production of an active ingredient, or a predecessor thereof, to one, or a few, fine chemical companies. The intellectual property of the product, and generally also the manufacturing process, stay with the customer. The customer-supplier relationship is governed by an exclusive supply agreement. At the beginning of cooperation, the customer provides a "tech package" which, in its simplest version, includes a laboratory synthesis description and SHE recommendations. In this case, the whole scale up, which comprises a factor of about one million (10 gram → 10 ton quantities), is done by the fine chemical company.
Endothelial cell loss may be aggravated or accelerated by intraocular trauma or surgery. A common scenario involves prolonged corneal swelling or edema following cataract surgery or other types of ocular surgery. Hence, patients with a history of Fuchs' dystrophy may be at a greater risk of corneal edema after ocular surgery as they have fewer functioning endothelial cells. FECD is classified into 4 stages, from early signs of guttae formation to end-stage subepithelial scarring. Diagnosis is made by biomicroscopic examination in the clinic. Other modalities, such as corneal thickness measurement (pachymetry), in-vivo confocal biomicroscopy, and specular microscopy can be used in conjunction. The exact pathogenesis is unknown but factors include endothelial cell apoptosis, sex hormones, inflammation, and aqueous humor flow and composition. Mutations in collagen VIII, a major component of Descemet's membrane secreted by endothelial cells, have been linked to the early-onset FECD. As a genetically heterogeneous disease, the phenotype, or clinical experience of patients with Fuchs dystrophy may reflect the combination of genetic contributors to the disease. Some genetic lesions correlate with more severe disease and earlier onset. Therefore, some individuals may experience symptoms of the disease at a much earlier age, while others may not experience symptoms until late in life. Genes include:
=== Reproduction === The same specimen of S. prima which had preserved a lizard in its stomach contents (NIGP 127587) also had several small eggs in its abdomen. Two eggs were preserved just in front of and above the pubic boot, and several more may lie underneath them on the slab. It is unlikely that they were eaten by the animal, as they are in the wrong part of the body cavity for the egg shells to have remained intact. It is more likely that they are unlaid eggs produced by the animal itself, proving the specimen to be a female. Each egg measured 36 mm (1.4 in) long by 26 mm (1.0 in) wide. The presence of two developed eggs suggests that Sinosauropteryx had dual oviducts and laid eggs in pairs, like other theropods.
== History == The discovery of phosphocreatine was reported by Grace and Philip Eggleton of the University of Cambridge and separately by Cyrus Fiske and Yellapragada Subbarow of the Harvard Medical School in 1927. A few years later David Nachmansohn, working under Meyerhof at the Kaiser Wilhelm Institute in Dahlem, Berlin, contributed to the understanding of the phosphocreatine's role in the cell.
Pat Wing I (パトウィング1, Pato Wingu Wan): Deka Red's personal fighter jet–themed Pat Wing that forms the head, torso, and upper legs of Deka Wing Robo. It also possesses the highest speed and mobility. Pat Wing II (パトウィング2, Pato Wingu Tsū): Deka Blue's personal VTOL-themed Pat Wing that forms the arms of Deka Wing Robo. It also possesses hovering capabilities, high stability, and wingtip blasters. Pat Wing III (パトウィング3, Pato Wingu Surī): Deka Green's personal cargo jet–themed Pat Wing that forms the lower legs of Deka Wing Robo. It is also highly confidential, making it suitable for the conveyance of dangerous goods. Pat Wing IV (パトウィング4, Pato Wingu Fō): Deka Yellow's personal stealth bomber–themed Pat Wing that forms the right foot of Deka Wing Robo. It also possesses high stealth and endurance capabilities, and is equipped with special arms such as flares and tear gas bombs. Pat Wing V (パトウィング5, Pato Wingu Faibu): Deka Pink's personal water bomber–themed Pat Wing that forms the left foot of Deka Wing Robo. It is also equipped with a speaker and fire-extinguishing capabilities.
Sources: en.wikipedia.org
Travel conditions were often extremely difficult due to the geography, climate, and lack of infrastructure across Spanish America in the early nineteenth century. The expedition frequently navigated dangerous and remote terrain. In the Orinoco basin, they traveled by canoe for weeks through dense rainforest and flooded savannahs, contending with swarms of mosquitoes and biting insects. Humboldt described suffering from fevers, likely caused by malaria or other tropical diseases, which affected both himself and Bonpland. They endured intense heat and humidity, particularly during their exploration of the Llanos and Amazonian lowlands. Food supplies were often insufficient or spoiled. Humboldt recounted periods of near-starvation, notably during their journey up the Cassiquiare Canal, when the group survived on minimal rations and local wild foods. Water was sometimes scarce or unsafe, and they risked illness from contaminated sources. The explorers faced physical dangers from local wildlife, including venomous snakes, jaguars, and crocodiles. Humboldt detailed an encounter with electric eels near Calabozo, where they observed the animals’ ability to stun horses during local fishing practices. Mountain ascents posed their own hazards. While climbing Chimborazo, Humboldt and Bonpland experienced altitude sickness, extreme cold, and exhaustion. Humboldt recorded severe headaches, nosebleeds, and difficulty breathing at high elevations.
The gastrointestinal tract (also called the GI tract, digestive tract, and the alimentary canal) is the tract or passageway of the digestive system that leads from the mouth to the anus. The tract is one of the largest of the body's systems. The GI tract contains all the major organs of the digestive system, in humans and other animals, including the esophagus, stomach, and intestines. Food taken in through the mouth is digested to extract nutrients and absorb energy, and the waste expelled at the anus as feces. Gastrointestinal is an adjective meaning of or pertaining to the stomach and intestines. Most animals have a "through-gut" or complete digestive tract. Exceptions are more primitive ones: sponges have small pores (ostia) throughout their body for digestion and a larger dorsal pore (osculum) for excretion, comb jellies have both a ventral mouth and dorsal anal pores, while cnidarians and acoels have a single pore for both digestion and excretion. The human gastrointestinal tract consists of the esophagus, stomach, and intestines, and is divided into the upper and lower gastrointestinal tracts. The GI tract includes all structures between the mouth and the anus, forming a continuous passageway that includes the main organs of digestion, namely, the stomach, small intestine, and large intestine. The complete human digestive system is made up of the gastrointestinal tract plus the accessory organs of digestion (the tongue, salivary glands, pancreas, liver and gallbladder).
Under normal conditions, acetyl-CoA is further oxidized by the citric acid cycle (TCA/Krebs cycle) and then by the mitochondrial electron transport chain to release energy. However, if the amounts of acetyl-CoA generated in fatty-acid β-oxidation challenge the processing capacity of the TCA cycle; i.e. if activity in TCA cycle is low due to low amounts of intermediates such as oxaloacetate, acetyl-CoA is then used instead in biosynthesis of ketone bodies via acetoacetyl-CoA and β-hydroxy-β-methylglutaryl-CoA (HMG-CoA). Furthermore, since there is only a limited amount of coenzyme A in the liver, the production of ketone bodies allows some of the coenzyme to be freed to continue fatty-acid β-oxidation. Depletion of glucose and oxaloacetate can be triggered by fasting, vigorous exercise, high-fat diets or other medical conditions, all of which enhance ketone production. Deaminated amino acids that are ketogenic, such as leucine, also feed TCA cycle, forming acetoacetate & ACoA and thereby produce ketones. Besides its role in the synthesis of ketone bodies, HMG-CoA is also an intermediate in the synthesis of cholesterol, but the steps are compartmentalised. Ketogenesis occurs in the mitochondria, whereas cholesterol synthesis occurs in the cytosol, hence both processes are independently regulated.
== Worldwide incidence by country == The total number of centenarians in the world is uncertain. The Population Division of the United Nations estimated that there were 23,000 in 1950, 110,000 in 1990, 150,000 in 1995, 209,000 in 2000, 324,000 in 2005, 455,000 in 2009, 675,000 in 2019 and 935,000 in 2024. These older estimates, however, did not take into account downward adjustments of national estimates made by several countries such as the United States. The UN estimated in 2012, as a result of these adjustments, that there were only 316,600 centenarians worldwide. The following table gives estimated centenarian populations by country, including both the latest and the earliest known estimates, where available. A study which received a 2024 Ig Nobel Prize found these numbers are inflated by welfare and pension fraud and poor record-keeping, neither of which are uniform across jurisdictions.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.